Get­ting to work on pipeline con­struc­tion, new Ipsen CEO forges $1B deal to buy Mer­ri­mack’s strug­gling Onivyde

Mer­ri­mack Phar­ma­ceu­ti­cals and Ipsen, two biotechs look­ing to re­or­ga­nize and move up in the world, have struck a bil­lion-dol­lar deal for a floun­der­ing can­cer ther­a­py. The Paris-based Ipsen is hand­ing over $575 mil­lion in cash and promis­ing up to $450 mil­lion in mile­stones to grab Mer­ri­mack’s US rights to Onivyde, ap­proved for pan­cre­at­ic can­cer. And new Ipsen CEO David Meek tells End­points that you can ex­pect more deals to come.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.